{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:02:14Z","timestamp":1781204534361,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jgar.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:48:34Z","timestamp":1571143714000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008\u20132014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART)"],"prefix":"10.1016","volume":"21","author":[{"given":"Shio-Shin","family":"Jean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.10.004_bib0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1749-7922-6-40","article-title":"Complicated intra-abdominal infections observational European study (CIAO study)","volume":"6","author":"Sartelli","year":"2011","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.jgar.2019.10.004_bib0010","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3389\/fmicb.2018.02888","article-title":"Carbapenem-resistant Enterobacteriaceae infections: Taiwan aspects","volume":"9","author":"Jean","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2019.10.004_bib0015","article-title":"Invasive pneumococcal disease in Indian adults: 11 years\u2019 experience","author":"Jayaraman","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0020","article-title":"Comparisons of clinical features and outcomes between Elizabethkingia meningoseptica and other glucose non-fermenting Gram-negative bacilli bacteremia in adult ICU patients","author":"Chen","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jmii.2015.08.026","article-title":"Clinical manifestations and bacteriological features of culture-proven Gram-negative bacterial arthritis","volume":"50","author":"Lin","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jmii.2016.08.022","article-title":"Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: a retrospective propensity-matched case control study","volume":"51","author":"Ting","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jmii.2015.07.008","article-title":"Gram-negative rod bacteremia after cardiovascular surgery: clinical features and prognostic factors","volume":"50","author":"Tago","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jmii.2017.08.016","article-title":"The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections","volume":"51","author":"Kuo","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2009.06.003","article-title":"Increasing extended-spectrum \u03b2-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia\/Pacific region: data from the SMART Study 2002\u20132006","volume":"59","author":"Ko","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jac\/dkw398","volume":"72","author":"Jean","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmii.2017.03.003","article-title":"The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan","volume":"50","author":"Tseng","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jmii.2017.03.007","article-title":"Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients","volume":"51","author":"Ismail","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.004_bib0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.004_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.004_bib0075","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2147\/IDR.S181085","volume":"11","author":"Jean","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2019.10.004_bib0080","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2019.10.004_bib0085","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and pharmacodynamic principles of anti-infective dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2019.10.004_bib0090","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-seventh informational supplement M100-S28","author":"CLSI","year":"2018"},{"key":"10.1016\/j.jgar.2019.10.004_bib0095","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000484868","article-title":"Mortality associated with hepatobiliary disease in Portugal between 2006 and 2012","volume":"25","author":"da Rocha","year":"2018","journal-title":"GE Port J Gastroenterol"},{"key":"10.1016\/j.jgar.2019.10.004_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","article-title":"Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen","volume":"17","author":"Kato","year":"2017","journal-title":"Drugs R&D"},{"key":"10.1016\/j.jgar.2019.10.004_bib0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/j.1552-4604.1984.tb02781.x","article-title":"Amikacin levels in the human biliary tract","volume":"24","author":"LeFrock","year":"1984","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2019.10.004_bib0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.19.2.352","article-title":"Amikacin sulfate levels in human serum and bile","volume":"19","author":"Berm\u00fadez","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0120","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/infdis\/124.Supplement_1.S77","article-title":"The use of gentamicin in peritoneal dialysis. I. Pharmacologic results","volume":"124","author":"Smithivas","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.004_bib0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.11.1.110","article-title":"Comparative penetration of amikacin, gentamicin, and penicillin G into exudate fluid in experimental sterile peritonitis","volume":"11","author":"MacGregor","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2165\/00003495-199244030-00008","article-title":"Imipenem\/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy","volume":"44","author":"Buckley","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2019.10.004_bib0135","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2019.10.004_bib0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01650757","article-title":"Bile levels of imipenem in patients with T-drain following the administration of imipenem\/cilastatin","volume":"16","author":"Mayer","year":"1988","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2019.10.004_bib0145","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/11319370-000000000-00000","article-title":"Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis","volume":"49","author":"Dahyot-Fizelier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2019.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1155\/1989\/41415","article-title":"The pharmacokinetics of the biliary excretion of ciprofloxacin","volume":"1","author":"Ball","year":"1989","journal-title":"HPB Surg"},{"key":"10.1016\/j.jgar.2019.10.004_bib0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1128\/AAC.36.3.677","article-title":"Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams","volume":"36","author":"Dan","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/clpt.1990.149","article-title":"Pharmacokinetics of cefepime in subjects with renal insufficiency","volume":"48","author":"Barbhaiya","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2019.10.004_bib0170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10156-007-0584-x","article-title":"Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment","volume":"14","author":"Higuchi","year":"2008","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2019.10.004_bib0175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijantimicag.2005.11.007","article-title":"Pharmacokinetics of cefepime in bile and gall bladder tissue after prophylactic administration in patients with extrahepatic biliary diseases","volume":"27","author":"Petrikkos","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.10.004_bib0180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007691-199206000-00008","article-title":"Tissue concentrations of cefepime in acute cholecystitis patients","volume":"14","author":"Okamoto","year":"1992","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jgar.2019.10.004_bib0185","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijantimicag.2007.04.012","article-title":"Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.10.004_bib0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/j.1875-9114.1991.tb02644.x","article-title":"Analysis of cefepime tissue penetration into human appendix","volume":"11","author":"Okamoto","year":"1991","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2019.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1099\/jmm.0.045799-0","article-title":"Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile","volume":"61","author":"Wozniak","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2019.10.004_bib0200","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.004_bib0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fmb.14.135","article-title":"Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options","volume":"10","author":"Jean","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2019.10.004_bib0210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/653932","article-title":"Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States","volume":"51","author":"Johnson","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:59Z","timestamp":1761990839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519302589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":42,"alternative-id":["S2213716519302589"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.004","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008\u20132014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}